Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Zymeworks BC Inc’s stock clocked out at $8.67, down -2.03% from its previous closing price of $8.85. In other words, the price has decreased by -$2.03 from its previous closing price. On the day, 0.41 million shares were traded. ZYME stock price reached its highest trading level at $8.925 during the session, while it also had its lowest trading level at $8.6.
Ratios:
To gain a deeper understanding of ZYME’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.41 and its Current Ratio is at 7.41. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On January 04, 2023, H.C. Wainwright reiterated its Neutral rating and also upped its target price recommendation from $10 to $8.
Jefferies Upgraded its Hold to Buy on December 20, 2022, whereas the target price for the stock was revised from $7.70 to $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 08 ’24 when Galbraith Kenneth sold 5,706 shares for $11.22 per share. The transaction valued at 63,996 led to the insider holds 23,762 shares of the business.
Moore Paul Andrew sold 2,339 shares of ZYME for $26,233 on Jan 08 ’24. The Chief Scientific Officer now owns 7,367 shares after completing the transaction at $11.22 per share. On Jan 08 ’24, another insider, Astle Christopher, who serves as the SVP & Chief Financial Officer of the company, sold 1,431 shares for $11.22 each. As a result, the insider received 16,050 and left with 6,503 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 611826304 and an Enterprise Value of 264251488. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.12 while its Price-to-Book (P/B) ratio in mrq is 1.32. Its current Enterprise Value per Revenue stands at 3.476 whereas that against EBITDA is -2.033.
Stock Price History:
Over the past 52 weeks, ZYME has reached a high of $13.14, while it has fallen to a 52-week low of $6.01. The 50-Day Moving Average of the stock is -20.22%, while the 200-Day Moving Average is calculated to be -1.83%.
Shares Statistics:
It appears that ZYME traded 567.85K shares on average per day over the past three months and 549450 shares per day over the past ten days. A total of 70.12M shares are outstanding, with a floating share count of 65.94M. Insiders hold about 7.41% of the company’s shares, while institutions hold 91.48% stake in the company. Shares short for ZYME as of 1711584000 were 5032315 with a Short Ratio of 8.86, compared to 1709164800 on 3310604. Therefore, it implies a Short% of Shares Outstanding of 5032315 and a Short% of Float of 8.1.
Earnings Estimates
The performance of Zymeworks BC Inc (ZYME) in the stock market is under the watchful eye of Zymeworks Inc. analysts actively contributing to its current rating.The consensus estimate for the next quarter is $8.20, with high estimates of $8.15 and low estimates of $8.10.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
